20 stories
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA. It has been studied as a metabolic regulator with roles in insulin sensitivity, exercise capacity, and aging-related metabolic decline. Most of the data sits in animal models, with limited human evidence.
On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee (PCAC) voted 7-5 with 2 abstentions to recommend adding MOTS-c to the Section 503A Bulks List. The vote overrode FDA career-staff briefing documents (released June 29-30) that recommended against inclusion, citing thin human clinical trial evidence and 503A historical use questions. The recommendation is advisory only; FDA rulemaking to actually add MOTS-c to the bulks list takes approximately 6-18 months from the date the agency decides to act.
Before the vote, MOTS-c had become a popular research peptide in the longevity and biohacking community, sold through compounding channels and online research-peptide vendors. State medical board enforcement actions have included it. ProPublica's 2026 reporting on the FDA's 2023 effective ban listed MOTS-c among the 19 injectable peptides at issue.
Human clinical evidence remains preliminary. Stories here cover the PCAC outcome, regulatory action, and any progress toward registered trials. See [[pcac]] and [[peptide-compounding]] for adjacent threads.
The UK's MHRA is investigating peptide clinics promoting BPC-157, MOTS-C, and Cortexin with unproven claims. Making medicinal claims classifies these products as medicines under UK law.
Health Secretary Kennedy announced on Joe Rogan's podcast that the FDA will soon reclassify about 14 peptides currently restricted from compounding pharmacies, aiming to curb gray-market sourcing.